No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.
A retrospective study explored the impact of preexisting cardiovascular disease on adverse events in patients with hematologic malignancies receiving BTK inhibitors.
HealthDay News — Conditions offering alternative explanations for lung cancer symptoms are associated with increased diagnostic intervals, according to a study published online Aug. 23 in the British ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback